Role of Hormone Therapy After Primary Surgery for Endometrioma: A Multicenter Retrospective Cohort Study

article OA: closed CC0 ⤵ 5 in-corpus citations
AI-generated summary by claude@2026-06+body, 2026-06-12

This study found that longer postoperative hormone therapy prolonged the recurrence-free interval for endometrioma but did not control residual disease, suggesting persistent hormone suppression is needed for prevention.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-12 · read from full text

This multicenter retrospective cohort study of 588 women assessed the rate and risk factors for recurrent endometrioma after primary surgery and evaluated how postoperative hormone therapy affected recurrence timing. Recurrence was defined sonographically as an endometrioma of at least 20 mm, occurring in 10.4% of patients, with cumulative recurrence rates of 2.2% at 1 year and 9.8% at 5 years. Higher serum CA125 level and posterior cul-de-sac (PCDS) obliteration were associated with increased recurrence risk, while longer postoperative hormonal therapy duration was associated with a longer recurrence-free interval; however, the therapy did not prolong the interval from end of treatment to first recurrence, and the authors concluded that persistent hormone suppression may be needed to prevent recurrence. This paper is centrally about endometriosis—specifically, postoperative hormone therapy to prevent recurrence after primary surgery for endometrioma.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 6,141 characters · extracted from oa-doi-fallback · 2 sections · click to expand

Abstract

Endometriosis is a major cause of disability in women, and 40% to 50% of patients experience disease recurrence by 5 years after surgery. This multicenter retrospective cohort study (N = 588) determined the rate and risk factors for recurrent endometrioma after primary surgery and examined the role of postoperative hormone therapy. When recurrence was defined by sonographic identification of the endometrioma (≥20 mm in size), 61 (10.4%) patients experienced disease recurrence. The cumulative recurrence rates at 1, 2, 3, and 5 years after surgery were 2.2%, 4.9%, 6.9%, and 9.8%, respectively. To determine the risk factors for recurrence, the clinical factors of patients with and without recurrence were compared. There was a significantly increased risk of recurrence with posterior cul-de-sac (PCDS) obliteration (P = .031) and higher serum cancer antigen 125 (CA125) level (P = .005). A longer postoperative hormonal therapy duration (P < .01), absence of PCDS obliteration (P = .036), and lower serum CA125 level (P = .014) were associated with longer recurrence-free interval on multivariate analysis using the Cox regression model. Postoperative hormone therapy prolonged the interval from the time of surgery to the first recurrence. However, it did not prolong the interval from the end of treatment to the first recurrence. Our results indicate that although long-term postoperative hormone therapy might maintain minimal disease status, it does not control residual disease. Therefore, persistent hormone suppression should be used to prevent disease recurrence. Similar content being viewed by others

References

Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. Fertil Steril. 2012;98(3):511–519. Vercellini P, Viganò P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol. 2014;10(5):261–275. Kim ML, Seong SJ. Clinical applications of levonorgestrel-releasing intrauterine system to gynecologic diseases. Obstet Gynecol Sci. 2013;56(2):67–75. Dunselman GA, Vermeulen N, Becker C, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29(3):400–412. Raffi F, Metwally M, Amer S. The impact of excision of ovarian endometrioma on ovarian reserve: a systemic review and metaanalysis. J Clin Endocrinol Metab. 2012;97(9):3146–3154. Guo SW. Recurrence of endometriosis and its control. Hum Reprod Update. 2009;15(4):441–461. Weir E, Mustard C, Cohen M, Kung R. Endometriosis: what is the risk of hospital admission, readmission, and major surgical intervention?. J Minim Invasive Gynecol. 2005;12(6):486–493. Friedlander RL. The treatment of endometriosis with danazol. J Reprod Med. 1973;10(4):197–199. Wright JA, Sharpe-Timms KL. Gonadotropin-releasing hormone agonist therapy reduces postoperative adhesion formation and reformation after adhesiolysis in rat models for adhesion formation and endometriosis. Fertil Steril. 1995;63(5):1094–1100. Leyland N, Casper R, Laberge P, Singh SS. Endometriosis: diagnosis and management. J Obstet Gynaecol Can. 2010;3232(7 suppl 2):s1–s32. Practice bulletin no. 114: management of endometriosis. Obstet Gynecol. 2010;116(1):223–236. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril. 1997;67(5):817–821. Johnson NP, Hummelshoj L; World Endometriosis Society Montpellier Consortium. Consensus on current management of endometriosis. Hum Reprod. 2013;28(6):1552–1568. Sakhel K, Abuhamad A. Sonography of adenomyosis. J Ultrasound Med. 2012;31(5):805–808. Van Holsbeke C, Van Calster B, Guerriero S, et al. Endometriomas: their ultrasound characteristics. Ultrasound Obstet Gynecol. 2010;35(6):730–740. Abbott JA, Hawe J, Clayton RD, Garry R. The effects and effectiveness of laparoscopic excision of endometriosis: a prospective study with 2–5 year follow-up. Hum Reprod. 2003;18(9):1922–1927. Busacca M, Marana R, Caruana P, et al. Recurrence of ovarian endometrioma after laparoscopic excision. Am J Obstet Gynecol. 1999;180(3 pt 1):519–523. Fedele L, Bianchi S, Zanconato G, Berlanda N, Raffaelli R, Fontana E. Laparoscopic excision of recurrent endometriomas: long-term outcome and comparison with primary surgery. Fertil Steril. 2006;85(3):694–699. Kikuchi I, Takeuchi H, Kitade M, Shimanuki H, Kumakiri J, Kinoshita K. Recurrence rate of endometriomas following a laparoscopic cystectomy. Acta Obstet Gynecol Scand. 2006;85(9):1120–1124. Koga K, Takemura Y, Osuga Y, et al. Recurrence of ovarian endometrioma after laparoscopic excision. Hum Reprod. 2006;21(8):2171–2174. Saleh A, Tulandi T. Reoperation after laparoscopic treatment of ovarian endometriomas by excision and by fenestration. Fertil Steril. 1999;72(2):322–324. Vignali M, Bianchi S, Candiani M, Spadaccini G, Oggioni G, Busacca M. Surgical treatment of deep endometriosis and risk of recurrence. J Minim Invasive Gynecol. 2005;12(6):508–513. Redwine DB. Conservative laparoscopic excision of endometriosis by sharp dissection: life table analysis of reoperation and persistent or recurrent disease. Fertil Steril. 1991;56(4):628–634. Yap C, Furness S, Farquhar C. Pre and post operative medical therapy for endometriosis surgery. Cochrane Database Syst Rev. 2004;(3):Cd003678. Vercellini P, DE Matteis S, Somigliana E, Buggio L, Frattaruolo MP, Fedele L. Long-term adjuvant therapy for the prevention of postoperative endometrioma recurrence: a systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2013;92(1):8–16. Sharpe KL, Bertero MC, Muse KN, Vernon MW. Spontaneous and steroid-induced recurrence of endometriosis after suppression by a gonadotropin-releasing hormone antagonist in the rat. Am J Obstet Gynecol. 1991;164(1 pt 1):187–194. Author information Authors and Affiliations Corresponding author Rights and permissions About this article Cite this article Seong, S.J., Kim, D., Lee, KH. et al. Role of Hormone Therapy After Primary Surgery for Endometrioma: A Multicenter Retrospective Cohort Study. Reprod. Sci. 23, 1011–1018 (2016). https://doi.org/10.1177/1933719115625841 Published: Issue date: DOI: https://doi.org/10.1177/1933719115625841

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosisendometrioma

MeSH descriptors

Endometriosis Endometriosis Endometriosis Hormones Adult Cohort Studies Disease-Free Survival Endometriosis Endometriosis Female Hormones Humans Recurrence Retrospective Studies Risk Factors Treatment Outcome

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (27)

Cited by (5)

Source provenance

europepmc
last seen: 2026-06-13T06:22:48.782012+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:21:19.813018+00:00
License: CC0 · commercial use OK